Epigenetic Study of Cohort of Monozygotic Twins With Hypertrophic Cardiomyopathy Due to MYBPC3 (Cardiac Myosin-Binding Protein C).

DNA methylation HCM MYBPC3 pathogenic variant epigenetics monozygotic twins phenotypic expressivity

Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
29 Oct 2024
Historique:
medline: 29 10 2024
pubmed: 29 10 2024
entrez: 29 10 2024
Statut: aheadofprint

Résumé

Hypertrophic cardiomyopathy is an autosomal dominant cardiac disease. The mechanisms that determine its variable expressivity are poorly understood. Epigenetics could play a crucial role in bridging the gap between genotype and phenotype by orchestrating the interplay between the environment and the genome regulation. In this study we aimed to establish a possible correlation between the peripheral blood DNA methylation patterns and left ventricular hypertrophy severity in patients with hypertrophic cardiomyopathy, evaluating the potential impact of lifestyle variables and providing a biological context to the observed changes. Methylation data were obtained from peripheral blood samples (Infinium MethylationEPIC BeadChip arrays). We employed multiple pair-matched models to extract genomic positions whose methylation correlates with the degree of left ventricular hypertrophy in 3 monozygotic twin pairs carrying the same founder pathogenic variant ( We present a unique pair-matched model, based on 3 monozygotic twin pairs carrying the same founder pathogenic variant and different phenotypes. This study provides further evidence of the pivotal role of epigenetics in hypertrophic cardiomyopathy variable expressivity.

Sections du résumé

BACKGROUND BACKGROUND
Hypertrophic cardiomyopathy is an autosomal dominant cardiac disease. The mechanisms that determine its variable expressivity are poorly understood. Epigenetics could play a crucial role in bridging the gap between genotype and phenotype by orchestrating the interplay between the environment and the genome regulation. In this study we aimed to establish a possible correlation between the peripheral blood DNA methylation patterns and left ventricular hypertrophy severity in patients with hypertrophic cardiomyopathy, evaluating the potential impact of lifestyle variables and providing a biological context to the observed changes.
METHODS AND RESULTS RESULTS
Methylation data were obtained from peripheral blood samples (Infinium MethylationEPIC BeadChip arrays). We employed multiple pair-matched models to extract genomic positions whose methylation correlates with the degree of left ventricular hypertrophy in 3 monozygotic twin pairs carrying the same founder pathogenic variant (
CONCLUSIONS CONCLUSIONS
We present a unique pair-matched model, based on 3 monozygotic twin pairs carrying the same founder pathogenic variant and different phenotypes. This study provides further evidence of the pivotal role of epigenetics in hypertrophic cardiomyopathy variable expressivity.

Identifiants

pubmed: 39470061
doi: 10.1161/JAHA.124.035777
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e035777

Auteurs

Alfonso Peñarroya (A)

Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.
Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.

Rebeca Lorca (R)

Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.
Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain.
Departamento de Biología Funcional Universidad de Oviedo Oviedo Spain.

José Julián Rodríguez Reguero (JJ)

Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.

Juan Gómez (J)

Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.
Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain.

Pablo Avanzas (P)

Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Unidad de Cardiopatías Familiares, Área del Corazón y Departamento de Genética Molecular Hospital Universitario Central Asturias Oviedo Spain.
Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORs) Madrid Spain.
Departamento de Medicina Universidad de Oviedo Oviedo Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) Oviedo Spain.

Juan Ramon Tejedor (JR)

Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.
Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain.

Agustín F Fernandez (AF)

Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.
Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain.

Mario F Fraga (MF)

Nanomaterials and Nanotechnology Research Center (CINN) Spanish National Research Council (CSIC) El Entrego Asturias Spain.
Health Research Institute of the Principality of Asturias (ISPA) Oviedo Asturias Spain.
Spanish Biomedical Research Network in Rare Diseases (CIBERER) Madrid Spain.
Institute of Oncology of Asturias (IUOPA), University of Oviedo Oviedo Asturias Spain.

Classifications MeSH